A series of 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-ones were prepared and tested for platelet aggregation inhibitory effect, cardiotonic activity and chronotropic activity. These compounds appeared to show selective inhibitory activity against platelet aggregation. Among them, 6-(4-ethoxycarbonylpiperidino)-7-nitro-3,4-dihydroquinoline-2(1H)-one (22f ) showed the most potent inhibitory activity and high selectivity. A divergent synthetic route to 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives has also been investigated.
efforts have been made to synthesize compounds which are significantly more active than acetylsalicylic acid in inhibiting platelet aggregation.
2) In our previous study of the synthesis of 6-(1-piperazinyl)-7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives, 3) it was found that the crude sample of 2-(4-methylamino)quinazolinyl derivative (1) (Fig. 1 ) exhibited good antiplatelet activity. However, further investigation revealed that pure 1 has only weak antiplatelet activity; the true active compound is 7-nitro-6-[1- (4-nitrosopiperazinyl) ]-3,4-dihydroquinolin-2(1H)-one 2, which was contaminated as an impurity in a screening sample of 1. Compound 2 had cardiotonic and chronotropic activities (CTA, CRA) in addition to antiplatelet activity (see Table 1 ).
In the present study, we focused on the structure of 2 and intended to separate its antiplatelet activity from its cardiovascular effects. This paper describes the synthesis of a series of derivatives of 2 and the details of their structure-activity relationship. In addition, a divergent synthetic route to 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-one derivatives has been investigated.
Chemistry
The lead compound 2 and its analogs, having an Nacylpiperazine ring (10, 12) or morpholine ring (7) at the 6-position of 3,4-dihydroquinoline-2(1H)-one, were prepared as shown in Chart 1. The acetal 4 obtained from commercially available 5-chloro-2-nitrobenzaldehyde 3 was converted to the 6-piperazinyl (6a) and 6-morpholino (6b) derivatives by a series of reactions based on the patent reported by Tominaga et al. 4) As the first step in the preparation of 2, we examined the N-nitrosation of 6a under conventional reaction conditions (NaNO 2 (4.0 eq) in 1 M hydrochloric acid, room temperature, for 4 h). The 1 H-NMR spectrum of the sole product from this reaction however showed, the presence of only two aromatic protons (d 7.10, 7 .30 ppm, both as a singlet). The product was identified with 2 by NMR, IR (NO 2 : 1523, 1375, 1348 cm
Ϫ1
) and FAB-MS (MϩH ϩ : m/z 306) spectra. Compound 2 was also identical to the impurity found in the initial screening sample of 1. The yield of 2 from 6a was 83%.
Simple N-nitrosation of 6a leading to 8 can be performed by the use of isoamyl nitrite in MeOH in 59% yield. Similarly, 6b underwent nitration at the 7-position by treatment with NaNO 2 (1.4 eq, AcOH/trifluoroacetic acid (TFA)ϭ4/1, room temperature, for 0.5 h) to give 7 in 43% yield. Although the actual reaction mechanism of these nitrations is not clear, it has been known that nitrous acid undergoes disproportionation to nitric acid and nitric oxide, 5) and there have been several precedents 6) involving nitration with nitrous acid. The preparation of the N-acetyl analog 10 was carried out by acetylation of 6a (95% yield, Ac 2 O in pyridine) followed by nitration at the 7-position of 9 (61% yield, 1.1 eq of NaNO 3 ) in TFA. The nitration of 9 can also be effected using NaNO 2 : 64% yield with NaNO 2 (1.0 eq) in 1 M hydrochloric acid; 86% yield with NaNO 2 (1.0 eq) in AcOH/TFAϭ4/1. It should be mentioned that, when the above nitration with NaNO 2 was carried out in AcOH alone, an inseparable mixture of 10/the 5-nitro isomerϭ7.5/1 was formed as evidenced by 1 H-NMR spectroscopy. 7) Compound 10 was hydrolyzed to 11 in 73% yield, and the N-formyl analog 12 was prepared by formylation of 11 in 45% yield.
At this stage, biological assay results of these compounds suggested that the presence of the 7-nitro group is essential to their inhibitory activity against platelet aggregation (see the next part of the text). As the 7-nitro group in the 3,4-dihydroquinoline-2(1H)-one system was expected to allow nucleophilic substitution at the 6-position, a plan was made for a divergent synthetic approach to the analogs, in which a compound having a 7-nitro group as well as a suitable leaving group at the 6-position is to be used as an intermediate.
A synthetic route to the above mentioned intermediate 19 is given in Chart 2. The aldehyde 14, prepared from commercially available 5-hydroxy-2-nitrobenzaldehyde 13, was sub-jected to Knoevenagel condensation with malonic acid to give 15 in 71% yield. After hydrogenation of the nitro group in 15, cyclization was effected simply by heating the reaction mixture at 70°C for 1 h, which gave 16 in 88% yield.
Nitration at the 7-position of 16 was examined under several conditions. When fuming nitric acid (1.0 eq) was used in combination with an acid anhydride (0°C, for 20-30 min), the desired 7-nitro derivative 17 always accompanied a considerable amount of the 7,8-dinitrated product (Ac 2 O with a small amount of conc. H 2 SO 4 : 17/7,8-dinitrated productϭ1/3; (CF 3 CO) 2 O: 17/7,8-dinitrated productϭ2/1) together with some of the starting material. Use of NaNO 3 (1.0 eq) was also discouraging, either forming a mixture of 17/8-nitro isomerϭ9/1 in TFA (room temperature, for 3 h) or giving the 8-nitro isomer in AcOH (100°C, for 1.5 h, 68% yield).
8) The best result was obtained again when 16 was reacted with a 1.0 eq of NaNO 2 in TFA (0°C, for 20 min, 88% yield of 17).
Compound 19, which was a key intermediate in our new synthetic approach, was prepared by demethylation of 17 with AlCl 3 (97% yield) followed by treatment of the resulting product (18) with CF 3 SO 2 Cl (79% yield). Nucleophilic substitution of 19 with cyclic aliphatic amines (20a-g, 21, see Fig. 2 ) was carried out in CH 3 CN at 80°C. This gave the desired analogs (22a-g, 23) in 4-51% yields.
Some of cyclic aliphatic amines (20d, e, g, 21), which were not commercially available, were prepared as shown in Chart 3. The aldehyde 26 was obtained from 24 in an overall yield of 40%: tert-butoxycarbonylation followed by the Dess-Martin oxidation. Preparation of the nitrile 28 was carried out by using 27 in an overall yield of 83%: tert-butoxycarbonylation and subsequent dehydration with trifluoroacetic anhydride (TFAA). The methyl ketone 29 was prepared from 28 with methyl magnesium iodide in 43% yield. The methyl sulfide 32 was prepared from 30 in an overall yield of 57%: tert-butoxycarbonylation, mesylation and finally thiomethylation. These N-tert-butoxycarbonyl (N-Boc) piperidines (26, 28, 29, 32) were used for the above-mentioned reaction of 19 after treatment with TFA. Also carried out was further de- Reagent and conditions: (a) MeOH, p-toluenesulfonic acid, reflux; in the case of XϭNH: (b) 1) piperazine, N,N-dimethylformamide, 80°C; 2) HCl, iso-PrOH-H 2 O, reflux; (c) 1) Ac 2 O, pyridine; 2) maloic acid, piperidine, reflux; 3) H 2 , Pd-C, AcOH; 4) cHCl, reflux; (d) NaNO 2 , 1 M HCl; in the case of XϭO: (b) 1) morpholine, 1,8-diazabicyclo [5, 4, 0] undec-7-ene, 100°C; 2) HCl, Acetone-H 2 O, 60°C; (c) 1) malonic acid, pyridine, piperidine, reflux; 2) H 2 , Pd-C, AcOH, MeOH, 80°C; (d) NaNO 2 , AcOH-TFA; (e) isoamyl-ONO, MeOH; (f ) Ac 2 O, pyridine; (g) NaNO 3 , TFA; (h) cHCl, 90°C; (i) HCOOH, 1,3-dicyclohexylcarbodiimide, CHCl 3 .
Chart 1. Synthesis of 6-Piperazinyl and 6-Morpholino Derivatives 2, 6a, 7, 8, 10-12 
Pharmacological Activities and Discussions
All 6-cyclic aliphatic amino-7-nitro-3,4-dihydroquinoline-2(1H)-ones (2, 8, 6a, 10-12, 22a-k) synthesized in this study were evaluated for their effect on platelet aggregation inhibitory activity (PIA) in rabbit platelet-rich plasma (PRP), 9) CTA and CRA on isolated guinea pig atria 10) by the procedures described in the Experimental Section. These results are summarized in Tables 1 and 2 .
When the 7-nitro group was removed from the lead compound 2, the PIA decreased significantly, as can be seen from the data of 8 in Table 1 . As N-nitroso compounds are generally known to be mutagenic or carcinogenic, 11) 2 was considered to be fatal for medicinal application. However, as shown in the cases of 11 and 6a, removal of the N-nitroso group uniformly resulted in the disappearance of the activities, except the CTA of 11.
One would anticipate that a certain electron-withdrawing group could act as a mimic of the nitroso group. Compounds 10 and 12 were prepared based on this assumption. Although the N-acetyl derivative 10 was devoid of PIA, we thought the PIA of the N-formyl derivative 12 deserved further investigation along this line. As can be seen from the data of 7, 22a and 22b in Table 2 , replacement of one nitrogen atom of the piperazine ring can be done without significant loss of PIA only by an oxygen atom, which is more electronegative than carbon and sulfur atoms. This suggested again that the introduction of an electron-withdrawing functionality to this portion could be promising.
While the sulfur-oxidized analogues (22h, i) of 22a gave rather discouraging results, the carbonyl-introduced analog 22c showed PIA activity comparable to that of 2. An additional appeal of 22c is in its improved selectivity: the effects of this compound to CTA and CRA are much weaker than those of 2.
Compounds having an electron-withdrawing functionality at the 4-position of the piperidine ring were also prepared. Among these compounds 22d-g, j, k, the 4-ethoxycarbonyl derivative 22f was found to have PIA as high as 2 with a much weaker CTA. It should be mentioned that the PIA of 22f is higher than that of cilostazol, 12) which has been applied clinically to treat thrombosis. 
Conclusion
The 7-nitro-3,4-dihydroquinolin-2(1H)-one derivatives, possessing various 6-membered heterocyclic rings at the 6-position, were synthesized and evaluated for PIA, CTA and CRA. Functional groups of the 4-position at the piperidine ring in 7-nitro-6-piperidino-3,4-dihydroquinolin-2(1H)-one have significant influence on both the potency of antiplatelet activity and the selectivity in antiplatelet, cardiotonic and chronotropic activities. Introduction of an ethoxycarbonyl group at the 4-position of the piperidine ring significantly enhanced the potency and selectivity of platelet aggregation inhibition. Further studies are in progress regarding the mechanism of action of this class of compounds based on their inhibitory activity against phosphodiesterase.
Experimental
Melting points were determined using a Yanagimoto melting point apparatus and are uncorrected.
1 H-NMR spectra were measured at 27°C (internal standard, Me 4 Si) with a Brucker DRX-500 (500 MHz) spectrometer, Brucker AMX-400 (400 MHz) spectrometer or a JEOL GX-270 (270 MHz) spectrometer. Mass spectra (MS) were taken on a JEOL JMS-SX102A (in FAB mode, glycerin, thioglycerin or m-nitrobenzyl alchol as a matrix) spectrometer. IR spectra were recorded with a Nicolet 510 FT-IR spectrometer. Column chromatography was carried out on silica gel (Silica gel 60, Merck). Thin layer chromatography (TLC) was performed on silica gel (precoated silica gel plate F 254 , layer thickness, 0.25 mm, Merck). Preparative TLC was performed on silica gel (precoated silica gel plate F 254 , layer thickness, 0.5 mm, Merck) or aminopropylated silica gel (precoated silica gel plate F 254 , layer thickness, 0.25 mm, NH TLC plate, Fuji Silysia Chemical). All organic extracts were dried over anhydrous MgSO 4 , then filtered. The solvent was removed with a rotary evaporator under reduced pressure.
5-Chloro-2-nitrobenzaldehyde Dimethyl Acetal (4) A solution of 2-nitro-5-chlorobenzaldehyde 3 (3 g, 16.2 mmol) and p-toluenesulfonic acid monohydrate (84 mg, 0.488 mmol) in MeOH (30 ml) was heated under reflux for 14 h. The reaction mixture was evaporated in vacuo, and the residue was partitioned between Et 2 O and saturated aqueous NaHCO 3 . The organic layer was dried and evaporated to give 4 (3.74 g, 100%) as a light yellow oil. 2-Nitro-5-(1-piperazinyl)benzaldehyde Hydrochloride (5a) A solution of 4 (5 g, 21.6 mmol) and anhydrous piperazine (9.3 g, 108 mmol) in N,N-dimethylformamide (DMF) (30 ml) was stirred at 80°C for 4 h. The reaction mixture was evaporated in vacuo, and the concentrate was partitioned between CH 2 Cl 2 and 1 M NaOH. The organic layer was washed with brine and concentrated to give a yellow oil. The residue was dissolved in a mixture of 2-propanol (35 ml) and concentrated HCl (2.6 ml), and the mixture was heated under reflux for 1 h with stirring. 5.57; N, 14.50. Found: C, 45.65; H, 5.38; N, 14.80 .
6-(1-Piperazinyl)-3,4-dihydroquinolin-2(1H)-one (6a)
A solution of 5a (54.0 g, 199 mmol) and acetic anhydride (19.7 ml, 209 mmol) in pyridine (500 ml) was stirred at room temperature for 3.5 h. After the addition of malonic acid (114 g, 1.09 mmol) and piperidine (6.9 ml, 70 mmol), the mixture was heated under reflux for 4 h with stirring. The reaction mixture was evaporated in vacuo and the residue was acidified with concentrated HCl. The precipitate was collected by filtration, washed successively with H 2 O, EtOH and Et 2 O and dried in vacuo to leave a yellow solid. The residue was hydrogenated (1 atm) in the presence of 10% Pd-C (6.5 g) in acetic acid (500 ml) at room temperature overnight. The catalyst was removed by filtration, and concentrated HCl (210 ml) was added to the filtrate. The mixture was heated under reflux for 3 h with stirring. After evaporation of the solvent, the precipitate was dissolved in H 2 O and washed with CHCl 3 . The aqueous solution was basified with 2 M NaOH and extracted with CHCl 3 . The organic extract was dried and evaporated to give 6a (33.8 g, 73%) as a white solid. Recrystallization was achieved from hexane-CH 2 Cl 2 -MeOH. mp 71-73°C. H, 7.41; N, 18.17. Found: C, 67.21; H, 7.45; N, 17.88 .
7-Nitro-6-[1-(4-nitrosopiperazinyl)]-3,4-dihydroquinolin-2(1H )-one (2)
To a solution of 6a (50 mg, 0.216 mmol) in 1 M HCl (0.65 ml), NaNO 2 (60 mg, 0.869 mmol) was added at 0°C, and the mixture was stirred for 4 h at room temperature. The precipitate was collected by filtration and dried in vacuo over P 2 O 5 to give 2 (55 mg, 83%) as a yellow solid. 
6-[1-(4-Acetylpiperazinyl)]-3,4-dihydroquinolin-2(1H)-one (9)
A solution of 6a (6.0 g, 25.9 mmol) and acetic anhydride (2.58 ml, 27.3 mmol) in pyridine (30 ml) was stirred at room temperature overnight. After evaporation of the solvent, the residue was partitioned between CHCl 3 and saturated aqueous NaHCO 3 . The organic layer was washed with saturated aqueous NH 4 Cl, dried, evaporated and crystallized from AcOEt to give 9 (6.70 g, 95%) as a white solid. 
6-[1-(4-Acetylpiperazinyl)]-7-nitro-3,4-dihydroquinolin-2(1H )-one (10)
To a solution of 9 (2.02 g, 7.39 mmol) in TFA (20 ml), NaNO 3 (0.69 g, 8.12 mmol) was added at 0°C, and the mixture was stirred at room temperature overnight. The reaction mixture was basified with 40% aqueous KOH and extracted with CHCl 3 . The organic layer was washed with brine, dried and evaporated to give 10 (1.44 g, 61%) as a pale orange solid. 7-Nitro-6-(1-piperazinyl)-3,4-dihydroquinolin-2(1H)-one (11) A solution of 10 (2.70 g, 8.48 mmol) in concentrated HCl (25 ml) was stirred at 90°C for 3 h. The reaction mixture was basified with 40% aqueous KOH at 0°C, and extracted with CHCl 3 . The organic layer was dried and evaporated to give 11 (1.67 g, 73%) as an orange solid. Recrystallization was achieved from CH 3 CN-MeOH. mp 280-281°C (dec. 
6-[1-(4-Formylpiperazinyl)]-7-nitro-3,4-dihydroquinolin-2(1H )-one (12)
To a stirred solution of 1,3-dicyclohexylcarbodiimide (DCC) (66 mg, 0.32 mmol) in CHCl 3 (0.5 ml), formic acid (0.024 ml, 0.64 mmol) in CHCl 3 (0.3 ml) was added at 0°C. After the mixture was stirred for 5 min, a solution of 11 (43 mg, 0.16 mmol) in pyridine (0.5 ml) was added to the mixture, and the stirring was continued for another 1 h. The reaction mixture was evaporated, and AcOEt was added to the concentrate. After filtration of the resulting suspension, silica gel column chromatography (CHCl 3 /MeOHϭ 50/1) of the filtrate gave 12 (22 mg, 45%) as an orange solid. Recrystallization was achieved from hexane-AcOEt-CH 5.40; N, 18.09. Found: C, 54.59; H, 5.28 ; N, 17.80.
5-Morpholino-2-nitrobenzaldehyde (5b)
A mixture of 4 (1.0 g, 4.3 mmol), morpholine (0.38 ml, 4.3 mmol) and 1,8-diazabicyclo [5, 4, 0] undec-7-ene (DBU) (0.64 ml, 4.3 mmol) was stirred at 100°C for 4 h. The reaction mixture was partitioned between AcOEt and H 2 O. Silica gel column chromatography (CHCl 3 ) of the organic layer gave 5-morpholino-2-nitrobenzaldehyde dimethyl acetal (1.06 g, 87%, Rf: 0.21, hexane/AcOEtϭ3/1) as a yellow oil. A solution of the dimethyl acetal (1.0 g, 3.54 mmol) in a mixture of acetone (40 ml) and 2 M HCl (10 ml) was stirred at 60°C for 1 h. After evaporation of the reaction mixture, the concentrate was partitioned between AcOEt and 2 M NaOH. The organic layer was dried and evaporated to give 5b (740 mg, 88%) as yellow needles. , 5.12; N, 11.86. Found: C, 56.02; H, 5.08; N, 12. 06.
6-Morpholino-3,4-dihydroquinolin-2(1H)-one (6b) To a refluxing solution of 5b (330 mg, 1.40 mmol) and piperidine (0.17 ml, 1.72 mmol) in pyridine (9 ml), malonic acid (204 mg, 1.96 mmol) was added, and the mixture was heated under reflux for 1 h. After evaporation of the solvent, the concentrate was acidified with 1 M HCl. The precipitate was collected by filtration, washed successively with H 2 O and with AcOEt and dried in vacuo to give a yellow solid. The solid was hydrogenated in the presence of 10% Pd-C (30 mg) in AcOH (3 ml) and MeOH (30 ml) for 8 h at room temperature. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. Silica gel column chromatography (CH 2 Cl 2 /MeOHϭ50/1) of the filtrate gave 6b (144 mg, 44%) as a white solid. 
6-Morpholino-7-nitro-3,4-dihydroquinolin-2(1H)-one (7)
To a solution of 6b (76 mg, 0.327 mmol) in a mixture of AcOH (4 ml) and TFA (1 ml), NaNO 2 (31 mg, 0.449 mmol) was added, and the mixture was stirred for 0.5 h at room temperature. After evaporation of the solvent, silica gel column chromatography (AcOEt) of the concentrate gave 7 (39 mg, 43%) as an orange solid. Recrystallization was achieved from hexane-AcOEt. mp 61-62°C. 
5-Methoxy-2-nitrobenzaldehyde (14)
To a stirred suspension of 5-hydroxy-2-nitrobenzaldehyde 13 (3 g, 18 .0 mmol) and Cs 2 CO 3 (5.86 g, 18.0 mmol) in DMF (20 ml), MeI (1.12 ml, 18.0 mmol) was added dropwise at 0°C. The stirring was continued for 3 d at room temperature. The reaction mixture was partitioned between AcOEt and H 2 O. Silica gel column chromatography (hexane/AcOEtϭ3/1) of the organic layer gave 14 (3.07 g, 94%) as colorless needles. Recrystallization was achieved from hexane-AcOEt. mp 80-81°C. 
6-Methoxy-3,4-dihydroquinolin-2(1H)-one (16)
A solution of 15 (2.58 g, 11.6 mmol) in AcOH (25 ml) was hydrogenated in the presence of 10% Pd-C (260 mg) for 14 h at room temperature. After the mixture was heated at 70°C for 1 h, the catalyst was removed by filtration and the filtrate was evaporated. The residue was partitioned between AcOEt and 1 M NaOH. The organic layer was evaporated to give 16 (1.82 g, 88%) as colorless needles. Recrystallization was achieved from hexane-AcOEt. mp 144-146°C. 1 3.87; N, 13.46. Found: C, 51.71; H, 3.92; N, 13.23 .
7-Nitro-6-trifluoromethanesulfonyloxy-3,4-dihydroquinolin-2(1H )-one (19) To a solution of 18 (0.40 g, 1.92 mmol) in DMF (4 ml), Et 3 N (0.29 ml, 2.09 mmol) was added at 0°C. After the mixture was stirred at 0°C for 5 min, CF 3 SO 2 Cl (0.22 ml, 2.09 mmol) was added, and stirring was continued for 18 h at room temperature. The reaction mixture was partitioned between AcOEt and saturated aqueous NH 4 Cl. The organic layer was washed with brine, dried and evaporated. Silica gel column chromatography (hexane/AcOEtϭ2/1) of the concentrate gave 19 (0.52 g, 79%) as a colorless powder. 
6-(4-Methylthiopiperidino)-7-nitro-3,4-dihydroquinolin-2(1H )-one (23)
A solution of 32 (300 mg, 1.30 mmol) in TFA (5 ml) was stirred at 0°C for 0.5 h. The mixture was allowed to stand to come to room temperature, then stirred for 1 h. The reaction mixture was made basic with 2 M NaOH at 0°C, extracted with a mixture of CH 2 Cl 2 and MeOH (5 : 1), dried and evaporated in vacuo to give a yellow oil (163 mg). A solution of the oil and 19 (70 mg, 0.308 mmol) in CH 3 CN (2 ml) was stirred at 90°C for 2 h. The reaction mixture was concentrated in vacuo. Preparative TLC (silica gel, hexane/AcOEtϭ1/1) of the residue gave 23 (29 mg, 29%) as orange plates. Recrystallization was achieved from hexane-AcOEt. mp 170-172°C. , 5.96; N, 13.07. Found: C, 55.92; H, 5.93; N, 13.21. 7-Nitro-6-piperidino-3,4-dihydroquinolin-2(1H)-one (22b) The title compound was obtained as orange plates (27%), starting from piperidine and following the method as described for 22a. Recrystallization was achieved from AcOEt. mp 202-203°C. . Rf: 0.21 (hexane/AcOEtϭ1/1). Anal. Calcd for C 14 H 17 N 3 O 3 : C, 61.08; H, 6.22; N, 15.26. Found: C, 60.93; H, 6.14; N, 15.15. 7-Nitro-6-(4-oxopiperidino)-3,4-dihydroquinolin-2(1H)-one (22c) The title compound was obtained as an orange solid (4%), starting from 4-piperidone monohydrate hydrochloride and following the method as described for 22a. Recrystallization was achieved from hexane-AcOEt. mp 251-252°C. 
6-(4-Ethoxycarbonylpiperidino)-7-nitro-3,4-dihydroquinolin-2(1H )-one (20f )
The title compound was obtained as orange plates (46%), starting from ethyl isonipecotate and following the method as described for 22a. Recrystallization was achieved from hexane-AcOEt. mp 173-175°C. , 5.47; N, 18.33. Found: C, 59.23; H, 5.31; N, 18.04 .
1-tert-Butoxycarbonyl-4-(hydroxymethyl)piperidine (25)
To a stirred solution of 4-(hydroxymethyl)piperidine 24 (2.0 g, 19.4 mmol) in a mixture of AcOEt (20 ml) and tetrahydrofuran (THF) (10 ml), di-tert-butyl dicarbonate (Boc 2 O) (4.23 g, 19.4 mmol) was added at room temperature. The mixture was stirred for 14 h at room temperature. After evaporation of the solvent, the concentrate was partitioned between AcOEt and saturated aqueous NH 4 Cl. The organic layer was washed with brine, dried and evaporated in vacuo to give 25 (4.17 g, 100%) as a colorless solid. Recrystallization was achieved from hexane-Et 2 O. mp 73-74°C. 64-2.77 (m, 2H), 3.47-3.53 (m, 2H), 4.06-4.20 (m, 2H 3 : C, 61.37; H, 9.83; N, 6.51. Found: C, 61.08; H, 10.09; N, 6.63 .
1-tert-Butoxycarbonyl-4-formylpiperidine (26) To a solution of 25 (200 mg, 0.929 mmol) in CH 2 Cl 2 (2 ml), Dess-Martin reagent 13) (394 mg, 0.929 mmol) was added at room temperature, and the mixture was stirred for 1 h at room temperature. After evaporation of the solvent, the residue was partitioned between AcOEt and 0.1 M NaOH. The organic layer was dried and evaporated. Silica gel column chromatography (hexane/AcOEtϭ1/1) of the concentrate gave 26 (79 mg, 40%) as a colorless oil. 1-tert-Butoxycarbonyl-4-cyanopiperidine (28) To a stirred solution of isonipecotamide 27 (5.0 g, 39.0 mmol) in a mixture of pyridine (24 ml) and CH 2 Cl 2 (30 ml), Boc 2 O (9.0 g, 41.2 mmol) in CH 2 Cl 2 (30 ml) was added at room temperature. The mixture was stirred for 40 min at room temperature. After the addition of TFAA (15 ml), the stirring was continued for 2 h at room temperature. After evaporation of the solvent, the concentrate was partitioned between Et 2 O and H 2 O. The organic layer was washed successively with 10% aqueous citric acid and with brine, dried and evaporated in vacuo over P 2 O 5 to give 28 (7.37 g, 83%) as colorless prisms. , 8.63; N, 13.32. Found: C, 62.55; H, 8.72; N, 13.27 1-tert-Butoxycarbonyl-4-methanesulfonyloxypiperidine (31) To a stirred solution of 4-hydroxypiperidine 30 (1.0 g, 9.69 mmol) in a mixture of CH 2 Cl 2 (10 ml) and 1.4-dioxane (10 ml), Boc 2 O (2.11 g, 9.67 mmol) was added at room temperature. The mixture was stirred for 2 h at room temperature. After evaporation of the solvent, the concentrate was partitioned between AcOEt and saturated aqueous NH 4 Cl. The organic layer was washed with brine, dried and evaporated to give a yellow oil. To a stirred solution of the oil in CH 2 Cl 2 (10 ml), Et 3 N (1.41 ml, 10.1 mmol) and methanesulfonyl chloride (0.75 ml, 9.69 mmol) were added at 0°C, and stirring was continued for 13 h at room temperature. The reaction mixture was partitioned between CH 2 Cl 2 and saturated aqueous NH 4 Cl. The organic layer was washed successively with saturated aqueous NaHCO 3 and with brine, dried and evaporated to give 31 (2.59 g, 96%) as colorless plates. Recrystallization was achieved from hexane-Et 2 O. mp 67-68°C.
1 H-NMR (CDCl 3 ) d: 1.46 (s, 9H), 1.78-1.85 (m, 2H), 1.93-1.99 (m, 2H), 3.04 (s, 3H), 3.26-3.35 (m, 2H), 3.67-3.74 (m, 2H), 4.85-3.92 (m, 1H NO 5 S: C, 47.30; H, 7.58; N, 5.01. Found: C, 47.14; H, 7.77; N, 5.27 . 1-tert-Butoxycarbonyl-4-methylthiopiperidine (32) To a stirred solution of 31 (700 mg, 2.51 mmol) in DMF (15 ml), sodium methanethiolate (237 mg, 3.38 mmol) was added at room temperature. The stirred mixture was heated at 80°C for 2 h. The reaction mixture was quenched by adding saturated aqueous NH 4 Cl and extracted with AcOEt. The organic layer was washed with H 2 O, dried and evaporated. Silica gel column chromatography (CH 2 Cl 2 ) of the concentrate gave 32 (343 mg, 59%) as a colorless oil. 7-Nitro-6-thiomorpholino-3,4-dihydroquinolin-2(1H )-one S-Oxide (22h) To a solution of 22a (40 mg, 0.136 mmol) in CH 2 Cl 2 (6 ml), mCPBA (23 mg, 0.133 mmol) was added at 0°C, and the mixture was stirred at 0°C for 2 h. The stirring was continued for 1 d at room temperature. The reaction mixture was partitioned between CH 2 Cl 2 and saturated aqueous NaHCO 3 . The organic layer was washed with brine, dried and evaporated. Preparative TLC (silica gel, AcOEt then CH 2 Cl 2 /MeOHϭ30/1) of the residue gave 22h (19 mg, 45%) as an orange solid. Recrystallization was achieved from hexane-AcOEt. mp 280-282°C. , 5.71; N, 12.39. Found: C, 53.02; H, 5.73; N, 12.53 .
6-(4-Methanesulfonylpiperidino)-7-nitro-3,4-dihydroquinolin-2(1H )-one (22k) To a solution of 23 (20 mg, 0.062 mmol) in CH 2 Cl 2 (4 ml), mCPBA (23 mg, 0.133 mmol) was added at 0°C, and the mixture was stirred for 17 h at room temperature. The reaction mixture was partitioned between CH 2 Cl 2 and saturated aqueous NaHCO 3 . The organic layer was washed with brine, dried and evaporated. Preparative TLC (silica gel, AcOEt) of the residue gave 22k (17 mg, 77%) as an orange solid. Recrystallization was achieved from hexane-AcOEt. mp 332-333°C. , 5.45; N, 11.83. Found: C, 50.81; H, 5.55; N, 11.56 .
CTA on Isolated Guinea Pig Atria Male Hartley guinea pigs (300-450 g) were sacrificed and then the left atria was isolated. CTA was measured in the isolated left atria, according to Horii et al. 10b) The left atria was stimulated electrically with a square-wave pulse stimulator at a frequency of 1 Hz and a voltage 20% above the threshold (duration: 5 ms). The atrium was suspended in Krebs-Henselite solution, aerated with 95% O 2 and 5% CO 2 at a temperature of 35°C, and stretched to a resting tension of 0.5 g. The physiological solution (in mM) consisted of the following: NaCl, 118; KCl, 4.7; CaCl 2 , 2.55; MgSO 4 1.18; KH 2 PO 4 , 1.18; NaHCO 3 , 24.88; glucose, 11.1. Before the construction of dose-response curves for each test compound, the cardiotonic response for epinephrine (10 Ϫ7 M) was established.
The inotropic potency was expressed as the ratio of the response to each compound to the response to epinephrine (10 Ϫ7 M). EC 30 values (micro mole per liter) represent the dose that produces a 30% increase in the epinephrine response.
CRA on Isolated Guinea Pig Atria Male Hartley guinea pigs (300-450 g) were sacrificed, then the right and left atria were isolated. CRA was measured on these isolated right and left atria. The atrium was suspended in Krebs-Henselite solution in the same condition described above. The chronotropic potency was expressed as the ratio of the response to each compound to the basal response. EC 10 values (micro mole per liter) represent the dose that produces a 10% increase in the basal response.
Platelet Aggregation in Rabbit PRP Rabbit (Japanese White) blood was obtained from the carotid artery in the presence of a 3.8% trisodium citrate aqueous solution (volume ratio 9 : 1), then centrifuged at 1000 rpm for 10 min at room temperature to give PRP. Platelet counts in PRP were determined using an automated particle counter (model F-800, Toa Medical Electronics Co., Ltd.). Platelet concentration was adjusted to 8-12ϫ10 8 platelets/ml with time-matched platelet-poor plasma (PPP), which was obtained from the precipitate fraction of PRP by centrifugation at 3000 rpm for 10 min at room temperature. The test compound or the control solution (2 ml) was added to the PRP (0.198 ml), then the mixture was incubated at 37°C with stirring for 1 min before the addition of ADP (20 ml, final conc. 20 mM). Changes in light transmission caused by platelet clotting were measured using an aggregometer (platelet aggregation tracer, Nicho Bioscience Co., Ltd.) until each trace reached a plateau. Platelet aggregation was expressed as the percentage change in light transmittance, with the difference of light transmittance between PRP and PPP as 100%. Antiplatelet activity was expressed as the percent inhibition of the control value.
